RLMD

Relmada Therapeutics Inc

6.28

Jul 02 • 04:00PM ET -0.11 (-1.72%)

Healthcare Biotechnology USA Small NASD

Peers: AXSM KYMR RYTM INCY NUVL BMRN NBIX VKTX KRYS MDGL

| Held by: VTI IWM VXF IWO XPH PSIL IWC VHT ITOT VFMO

Scroll to Statements

Index	RUT
Market Cap	658.71M
Enterprise Value	424.75M
Income	-58.88M
Sales	0.00M
Book/sh	2.09
Cash/sh	2.23
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Jun 20, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.01
P/C	2.82
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	18.26
Current Ratio	18.26
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.11
EPS next Y	-0.96
EPS next Q	-0.20
EPS this Y	42.99%
EPS next Y	-16.73%
EPS next 5Y	13.22%
EPS past 3/5Y	35.03% 17.54%
Sales past 3/5Y	- -
EPS Y/Y TTM	55.59%
Sales Y/Y TTM	-
EPS Q/Q	61.90%
Sales Q/Q	-
Earnings	May 12 AMC
EPS/Sales Surpr.	-9.84% -

Insider Own	13.80%
Insider Trans	0.00%
Inst Own	71.90%
Inst Trans	29.63%
ROA	-44.77%
ROE	-48.83%
ROIC	-26.92%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.33%
SMA50	-9.12%
SMA200	29.81%
Trades

Shs Outstand	104.89M
Shs Float	90.42M
Short Float	6.70%
Short Ratio	3.84
Short Interest	6.06M
52W High	8.00 -21.50%
52W Low	0.55 1041.82%
Volatility	7.57% 6.88%
ATR (14)	0.44
RSI (14)	42.80
Beta	0.45
Rel Volume	0.92
Avg Volume	1.58M
Volume	1,448,886

Perf Week	-2.64%
Perf Month	-2.18%
Perf Quarter	-11.55%
Perf Half Y	38.63%
Perf YTD	30.02%
Perf Year	944.75%
Perf 3Y	155.28%
Perf 5Y	-80.74%
Perf 10Y	-31.44%
Recom	1.00
Target Price	12.67
Prev Close	6.39
Price	6.28
Change	-1.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-26	Initiated	H.C. Wainwright	Buy	$12
Mar-24-26	Initiated	Piper Sandler	Overweight	$12
Jan-23-26	Resumed	Leerink Partners	Outperform	$8
Dec-22-25	Initiated	Jefferies	Buy	$69
Nov-19-25	Upgrade	Mizuho	Neutral → Outperform	$10
Dec-05-24	Downgrade	Mizuho	Outperform → Neutral	$23 → $1
Sep-17-24	Upgrade	Jefferies	Hold → Buy	$3.50 → $13
Jun-05-24	Downgrade	Goldman	Neutral → Sell	$3 → $2
Oct-14-22	Downgrade	Truist	Buy → Hold	$90 → $10
Oct-14-22	Downgrade	Guggenheim	Buy → Neutral
Oct-14-22	Downgrade	Goldman	Buy → Neutral	$81 → $8
Oct-13-22	Downgrade	Oppenheimer	Outperform → Perform	$64 → $7
Nov-18-21	Initiated	Mizuho	Buy	$50
May-20-21	Resumed	Goldman	Buy	$78
Oct-28-20	Downgrade	Goldman	Buy → Neutral	$69 → $40
Jul-14-20	Initiated	Oppenheimer	Outperform	$75
May-04-20	Initiated	SunTrust	Buy	$75
Apr-21-20	Initiated	Goldman	Buy	$63
Jan-27-20	Initiated	Jefferies	Buy	$75
Jan-10-20	Initiated	SVB Leerink	Outperform	$50

Show Previous Ratings

Jun-29-26 07:00AM	Relmada Therapeutics Joins Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-11-26 07:00AM	Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program (GlobeNewswire)
May-28-26 07:00AM	Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-26 01:02AM	Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
May-12-26 04:05PM	Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
May-06-26 07:00AM	Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026 (GlobeNewswire) +6.94%
May-05-26 07:00AM	Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 (GlobeNewswire)
Mar-19-26 11:01PM	Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
08:14PM	Relmada Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
04:01PM	Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update (GlobeNewswire)
Mar-12-26 07:00AM	Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 (GlobeNewswire)
03:00AM	BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director (TMX Newsfile)
Mar-09-26 07:00PM	50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today (24/7 Wall St.) +61.12% -7.67%
04:30PM	Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
08:48AM	Why Is Relmada Therapeutics Stock Soaring Monday? (Benzinga)
07:05AM	Loading…
07:05AM	Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing (GlobeNewswire)
07:00AM	Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Feb-26-26 12:07PM	Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders (PR Newswire)
Jan-12-26 07:00AM	Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications (GlobeNewswire)
Dec-22-25 09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly)
Dec-03-25 07:30AM	Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology (GlobeNewswire)
Nov-20-25 10:15AM	This Stock Is Up 704% in 2025 But Has No Products to Its Name (Barchart)
Nov-14-25 12:02AM	Relmada Therapeutics Inc (RLMD) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-13-25 04:01PM	Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates (GlobeNewswire)
Nov-07-25 07:30AM	Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 (GlobeNewswire)
Nov-04-25 07:09AM	Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +25.91%
07:01AM	Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer (GlobeNewswire)
Oct-07-25 07:30AM	Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 (GlobeNewswire)
Sep-23-25 07:24PM	Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data (Insider Monkey)
Sep-16-25 11:20AM	Sidoti Events, LLC's Virtual September Small-Cap Conference (ACCESSWIRE)
09:00AM	Loading…
09:00AM	Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Sep-10-25 07:15AM	Relmada Issues Mid-Year CEO Letter to Shareholders (GlobeNewswire)
Sep-03-25 04:10PM	Exclusive: Relmada CEO says his recent buy reflects significant undervaluation (Investing.com) -6.80%
Sep-02-25 03:53AM	Relmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer Study (Insider Monkey) +26.79%
Aug-07-25 04:05PM	Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC (GlobeNewswire)
Jul-31-25 07:00AM	Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 (GlobeNewswire)
Jul-15-25 08:00AM	Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 (GlobeNewswire)
Jul-09-25 08:00AM	DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors (GlobeNewswire)
Jun-17-25 07:00AM	Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology (GlobeNewswire)
May-13-25 09:08AM	Q1 2025 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... (GuruFocus.com)
May-12-25 04:01PM	Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.05%
May-08-25 07:30AM	Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire) +5.64%
Apr-28-25 01:38PM	Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 (GlobeNewswire) -44.64%
Apr-27-25 09:00AM	UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
Apr-24-25 08:00AM	Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data (GlobeNewswire) +6.86%
Apr-14-25 08:41AM	UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
07:30AM	Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
Mar-28-25 07:05AM	Q4 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... (GuruFocus.com)
Mar-27-25 08:07PM	Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:05PM	Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update (GlobeNewswire)
Mar-26-25 09:00AM	Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 (GlobeNewswire)
Mar-25-25 07:30AM	Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. (GlobeNewswire) +6.09%
Feb-07-25 06:46AM	Relmada acquires Tourettes therapy rights from Asarina (Pharmaceutical Technology) -9.62%
Feb-06-25 07:30AM	Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB (GlobeNewswire) -10.00%
Dec-09-24 07:30AM	Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 (GlobeNewswire) +5.14%
Dec-05-24 07:36AM	Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile (TipRanks) -28.57%
Dec-04-24 07:30AM	Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance (GlobeNewswire) -77.26%
Nov-19-24 09:00AM	Relmada Therapeutics to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-14-24 07:30AM	Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease (GlobeNewswire)
Nov-10-24 09:02PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024 (Market Exclusive)
Nov-08-24 02:28AM	Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Nov-07-24 04:32PM	Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-04-24 04:30PM	Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Sep-12-24 01:07AM	Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD) (GuruFocus.com) +8.28%
01:06AM	Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares (GuruFocus.com)
Aug-12-24 09:35AM	Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-08-24 01:51PM	Q2 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -29.01%
Aug-07-24 04:05PM	Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Aug-05-24 07:30AM	Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire) -5.83%
Jun-18-24 08:30AM	Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry (PR Newswire)
Jun-10-24 07:30AM	Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire) +5.76%
Jun-03-24 07:30AM	Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference (PR Newswire)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-11-24 08:41AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 06:20AM	Q1 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:40AM	Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-08-24 09:55PM	RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (PR Newswire)
May-06-24 07:30AM	Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 (PR Newswire)
Mar-20-24 10:27AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript (Insider Monkey) -17.41%
06:27AM	Q4 2023 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:52PM	RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
05:31PM	Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results (GuruFocus.com)
04:15PM	Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results (PR Newswire)
Mar-12-24 07:30AM	Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024 (PR Newswire)
Mar-05-24 07:30AM	Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (PR Newswire)
Feb-01-24 03:02PM	Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares (GuruFocus.com) +16.03%
Jan-05-24 05:12PM	Health Care Roundup: Market Talk (The Wall Street Journal) +7.27%
Jan-04-24 07:30AM	Relmada Therapeutics Provides Corporate Update (PR Newswire) -31.68%
Dec-29-23 08:47AM	11 Best Psychedelic Stocks to Buy in 2024 (Insider Monkey) +9.23%
Dec-20-23 02:39PM	5 Most Promising Psychedelic Stocks According to Hedge Funds (ready to review) (Insider Monkey)
02:14PM	5 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey)
Nov-10-23 01:57PM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 06:47PM	Relmada Therapeutics Inc (RLMD) Reports Third Quarter 2023 Financial Results (GuruFocus.com)
04:01PM	Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-03-23 07:30AM	Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023 (PR Newswire)
Oct-11-23 08:31AM	Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting 2023 (PR Newswire)
Oct-09-23 07:30AM	Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit (PR Newswire)

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Pharm.D.Dr. Sergio Traversa M.B.A.

R.Ph.Mr. Maged S. Shenouda M.B.A.

COO & DirectorMr. Paul E. Kelly M.B.A.

M.B.A.Mr. Charles S. Ence CPA

VP & Head of Clinical OperationsMs. Gina DiGuglielmo

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TRAVERSA SERGIO	Chief Executive Officer	Dec 15 '25	Buy	4.12	27,500	113,300	1,300,000	Dec 16 09:30 AM
Shenouda Maged	Chief Financial Officer	Dec 15 '25	Buy	4.12	11,665	48,060	800,000	Dec 16 09:30 AM
Shenouda Maged	Chief Financial Officer	Nov 05 '25	Buy	2.20	500,000	1,100,000	788,335	Nov 06 07:30 AM
Ence Chuck	CAO and COO	Nov 05 '25	Buy	2.20	136,000	299,200	403,931	Nov 06 07:30 AM
TRAVERSA SERGIO	Chief Executive Officer	Nov 05 '25	Buy	2.20	272,500	599,500	1,272,500	Nov 06 07:30 AM
Kelly Paul Edward	Chief Operating Officer	Nov 05 '25	Buy	2.20	90,000	198,000	502,295	Nov 06 07:30 AM
TRAVERSA SERGIO	Chief Executive Officer	Aug 27 '25	Buy	0.67	129,455	86,735	944,024	Aug 28 04:56 PM
TRAVERSA SERGIO	Chief Executive Officer	Aug 26 '25	Buy	0.62	80,545	49,938	814,569	Aug 28 04:56 PM
TRAVERSA SERGIO	Chief Executive Officer	Aug 28 '25	Buy	0.74	55,976	41,422	1,000,000	Aug 28 04:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

RLMD

Relmada Therapeutics Inc

Upgrade your Finviz experience